Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
AstraZeneca (AZN.US) Experimental Lung Disease Drug Meets Targets in Late-Stage Trials; Stock Rises 4% Pre-Market
Recommend 1 Positive 1 Negative 1 |
||||
|
||||
|
AstraZeneca (AZN.US) announced that its experimental lung disease drug achieved targets in two late-stage clinical trials, boosting its US stock price by nearly 4% pre-market. The company stated that the respiratory treatment drug Tozorakimab can reduce the incidence of chronic obstructive pulmonary disease in former smokers and the general population, showing better results compared to a placebo. (sw/m) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
